Association Between Cyclin-Dependent Kinase 4/6 Inhibitors and Nephrotoxicity in Patients with Breast Cancer: A Systematic Review and Meta-analysis
Description
This study conducted a meta-analysis of 17 randomized controlled trials involving 19,638 patients to assess the risk of nephrotoxicity associated with cyclin-dependent kinase (CDK) 4/6 inhibitors in breast cancer treatment. The analysis found a significant increase in all-grade nephrotoxic adverse events (AEs), including elevated blood creatinine, acute kidney injury, and renal impairment (RR = 3.12, 95% CI [2.11, 4.63]). The incidence of grade 3 or higher nephrotoxicity was also notably higher in treated patients (RR = 3.12, 95% CI [1.74, 5.58]). Subgroup analyses indicated differential risks across the four CDK4/6 inhibitors. These results underscore the importance of clinicians closely monitoring renal function in patients receiving CDK4/6 inhibitors.